Metabolic syndrome, androgens, and hypertension

Current Hypertension Reports

Volumn 13, Issue 2, 2011, Pages 158-162

  Moulana, Mohadetheh ^a   Lima, Roberta ^a   Reckelhoff, Jane F ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Aging; Androgens; Cardiovascular disease; Inflammation; Menopause; Metabolic syndrome; Polycystic ovary syndrome; Postmenopausal hypertension; Testosterone

Indexed keywords

ANDROGEN; ESTRADIOL; LEPTIN; ROSIGLITAZONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ANDROGEN DEFICIENCY; BODY MASS; BODY WEIGHT; DISEASE PREDISPOSITION; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; NONHUMAN; OBESITY; REVIEW; SEX DIFFERENCE; TESTOSTERONE BLOOD LEVEL;

ANDROGENS; FEMALE; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; OBESITY;

EID: 79955962031     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-011-0184-0     Document Type: Review

References (49)

1. Yach D, Stuckler D, Brownell KD. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med. 2006;12:62-6. (Pubitemid 43050076)
2. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303:235-41.
3. Tamler R. Diabetes, obesity and erectile dysfunction. Gender Medicine. 2009;6:4-16.
4. Stanworth RD, Jones TH. Testosterone in obesity, metabolic syndrome and type 2 diabetes. Front Horm Res. 2009;37:74-90.
5. Azziz R, Carmina E, Dewailly D, et al. Position statement: Criteria for defining polycystic ovary syndrome: An Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91:4237-5.
6. Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Muhlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Endocrinol Metabol. 2000;85:645-51. (Pubitemid 32273648)
7. Traish TM, Saad F, Feeley RJ, Guay A. The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl. 2009;30:477-94. This is a concise review that discusses the known effects of androgens on various cardiovascular systems and hypertension.
8. Malkin CJ, Channer KS, Jones TH. Testosterone and heart failure. Curr Opin Endocrinol Diabetes Obes. 2010;17:262-8.
9. Carrero JJ, Qureshi AR, Parini P, et al. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol. 2009;20:613-20.
10. Shabsigh R, Arver K, Channer KS, et al. The triad of erectile dysfunction, hypogonadism and the metabolic syndrome. Int J Clin Prac. 2008;62:791-8. (Pubitemid 351533668)
11. Allan CA, McLachlan RI. Androgens and obesity. Curr Opin Endocrinol Diabetes Obes. 2010;17:224-32.
12. Traish AM, Kypreos KE. Testosterone and cardiovascular disease: An old idea with modern clinical implications. Atherosclerosis 2010 Sep 22 (Epub ahead of print).
13. Akishita M, Fukai S, Hashimoto M, et al. Association of low testosterone with metabolic syndrome and its components in middle-aged Japanese men. Hypertens Res. 2010;33(6):587-91.
14. Maggio M, Laurentiani F, Ceda GP, et al. Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch Intern Med. 2007;167:2249-54. (Pubitemid 350106746)
15. Khaw K, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circ. 2007;116:2694-701. (Pubitemid 350291241)
16. Whitaker EM, Shaw MA, Hervey GR. Plasma oestradiol-17 beta and testosterone concentrations as possible causes of the infertility of congenitally obese Zucker rats. J Endocrinol. 1983;99:485-90. (Pubitemid 14244078)
17. Hill JW, Elias CF, Williams KW, et al. Direct insulin and leptin action on pro-opiomelanocortin neurons is required for normal glucose homeostasis and fertility. Cell Metab. 2010;11:286-97.
18. Perez-Torres I, Roque P, El Hafidi M, et al. Association of renal damage and oxidative stress in a rat model of metabolic syndrome. Influence of gender. Free Rad Biol Med. 2009;43:761-71.
19. Chakrabarti SK, Wen Y, Dobrian AD, et al. Evidence for activation of inflammatory lipoxygenase pathways in visceral adipose tissue of obese Zucker rats. Am J Physiol Endocrinol Metab. 2011;300(1):E175-87.
20. Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrin Metab. 2004;89:3313-8. (Pubitemid 38951897)
21. Svartberg J, von Muhlen D, Sundsfjord J, Jorde R. Wait circumference and testosterone levels in community dwelling men. The Tromso study. Eur J Epidemiol. 2004;19:657-63. (Pubitemid 41175133)
22. Neilsen TL, Hagen C, Wraae K, et al. Visceral and subcutaneous adipose tissue assessed by magnetic resonance imaging in relation to circulating androgens, sex hormone binding globulin, and luteinizing hormone in young men. J Clin Endocrin Metab. 2007;92:2696-705. (Pubitemid 47037378)
23. Vermeulen A, Kaufman JM, Deslypere JP, Thomas G. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrin Metab. 1993;76:1140-6. (Pubitemid 23155426)
24. Giagulli VA, Kaufman JM, Vermeulen A. Pathogenesis of the decreased androgen levels in obese men. J Clin Endocrin Metab. 1994;79:997-1000. (Pubitemid 24342237)
25. Isidori AM, Caprio M, Strollo F, et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrin Metab. 1999;84:3673-80. (Pubitemid 30645224)
26. Kapoor D, Channer KS, Jones TH. Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes. Diab Vasc Dis Res. 2008;5:135-7. These authors describe studies in which obese men were given a thiazolidinedione, rosiglitazone, a PPARγ agonist, to improve insulin sensitivity. The drug also increases serum testosterone levels.
27. Olivares A, Mendez JP, Zambrano E, et al. Reproductive axis function and gonadotropin microheterogeneity in a male rat model of diet-induced obesity. Gen Com Endocrinol. 2010;166:356-64.
28. Cattaneo L,De Gennaro ColonnaV, ZoliM, et al. Characterization of the hypothalamo-pituitary-IGF-1 axis in rats made obese by overfeeding. J Endocrinol. 1996;148:347-53.
29. Cano P, Jimenez-Ortega V, Larrad A, et al. Effect of a high-fat diet on 24-h pattern of circulating levels of prolactin, luteinizing hormone and glucose, and pineal melatonin content, in rats. Endocrine. 2008;33:118-25.
30. Ikeda Y, Aihara K, Akaike M, et al. Androgen receptor counteracts Doxorubicin-induced cardiotoxicity in male mice. Mol Endocrinol. 2010;24:1338-48.
31. Sieveking DP, Lim P, Chow RW, et al. A sex specific role for androgens in angiogenesis. J Exp Med. 2010;207:345-52.
32. Mah PM, Wittert GA. Obesity and testicular function. Molec Cell Endocrinol. 2010;316:180-6.
33. Marin P, Holmang S, Gustafsson C, et al. Androgen treatment of abdominally obese men. Obesity Res. 1993;1:245-51.
34. Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrin Metab. 2007;92:3844-53. (Pubitemid 47607632)
35. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001;37:1199-208. (Pubitemid 34163570)
36. Reckelhoff JF, Zhang H, Granger JP. Testosterone exacerbates hypertension and reduces pressure-natriuresis in male spontaneously hypertensive rats. Hypertension. 1998;31:435-9.
37. Yanes LL, Iliescu R, Sartori-Valinotti JC, et al. Testosterone-dependent hypertension and upregulation of intrarenal angiotensinogen in Dahl salt-sensitive rats. Am J Physiol Reg Integr Comp Physiol. 2009;296:F771-9.
38. Schultheiss D, Machtens S, Jonas U. Review article: Testosterone therapy in the ageing male: What about the prostate? Andrologia. 2004;36:355-65.
39. Mazer NA. A novel spreadsheet method for calculating free serum concentrations of testosterone, dihydrotestosterone, estradiol, sterone, and cortisol: with illustrative examples from male and female populations. Steroids. 2009;74:512-9.
40. Harvie MN, Pegington M, Mattson MP, et al. The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond) 2010 Oct 5 (Epub ahead of print).
41. Diamanti-Kandarakis E. Polycystic ovarian syndrome; pathophysiology, molecular aspects and clinical implications. Exp Rev Mol Med. 2008;10:1-21. (Pubitemid 351338213)
42. Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocrine. 2006;30:13-7. (Pubitemid 46020325)
43. Sahin Y, Unluhizarci K, Yilmazsoy A, et al. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Clin Endocrinol. 2007;67:904-8. (Pubitemid 350135135)
44. Manneras L, Cajander S, Holmang A, et al. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinol. 2007;148:3781-91. (Pubitemid 47105840)
45. Baba T, Endo T, Honnma H, et al. Association between polycystic ovary syndrome and female-to-male transsexuality. Hum Reprod. 2006;22:1011-6.
46. Ho SC, Wu S, Chen SG, Sham A. Menopausal transition and changes of body composition: a prospective study in Chinese perimenopausal women. Int J Obesity. 2010;34:1265-74. This study showed that with menopause transition, in the absence of any weight gain, the fat deposition in women changes from subcutaneous to visceral. This study supports a previous study [48].
47. Ozbey N, Sencer E, Molvalillar S, Orhan Y. Body fat distribution and cardiovascular disease risk factors in pre- and postmenopausal obese women with similar BMI. Endocrinol J. 2002;49:503-9. (Pubitemid 34988241)
48. Nedungadi TP, Clegg DJ. Sexual dimorphism in body fat distribution and risk for cardiovascular diseases. J Cardiovasc Transl Res. 2009;2:321-7.
49. Reckelhoff JF, Fortepiani LA. Novel mechanisms responsible for postmenopausal hypertension. Hypertension. 2004;43:918-23. (Pubitemid 38579888)